Press Release issued Jan 13, 2021: Frontida BioPharm, Inc., a pharmaceutical Contract Development and Manufacturing Organization based in Philadelphia and Chicago areas, announced today the launch of its new Category 1 (CAT.ONETM) in vitro testing and evaluation services to support the development and regulatory approvals for abuse-deterrent formulations of pain management and Central Nervous System (CNS) targeted therapies.
Press ReleasesJanuary 14, 2021
Frontida BioPharm, Inc. Launches CAT.one Testing to Support Abuse-Deterrent Product Development
Frontida BioPharm, Inc. Announces Highly Potent Compound Contract Manufacturing Suite to Support Existing Product Development and Manufacturing Capabilities
August 19, 2020
Frontida BioPharm, Inc. has Been Recognized as a Minority Owned Contract Development and Manufacturing Organization
December 14, 2020